Eton Pharma Q2 FY26 EPS swings to GAAP profit of $0.35; revenue more than doubled to $37.6 million

PUBT · 1d ago
Eton Pharma Q2 FY26 EPS swings to GAAP profit of $0.35; revenue more than doubled to $37.6 million
  • Eton Pharmaceuticals posted Q2 2026 revenue of USD 37.6 million, more than doubled from a year earlier on portfolio growth.
  • Net income swung to USD 11.6 million, with GAAP diluted EPS at USD 0.35.
  • Adjusted EBITDA rose to USD 16.2 million, lifting the adjusted EBITDA margin to 43% of revenue.
  • 2026 revenue outlook lifted to exceed USD 145 million, with an adjusted EBITDA margin target raised to at least 35%.
  • HEMANGEOL relaunched May 1; about 95% of existing patients transitioned by end-June, with ASN-001 licensed for a potential 2027 NDA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809880) on August 13, 2026, and is solely responsible for the information contained therein.